周吉银,邓皤,周世文.我国医学伦理委员会存在的问题及建议[J].中国临床药理学杂志,2017,33(4):365-368.Zhou JY,Deng F,Zhou SW.Problems and countermeasures of medical ethics committee in China[J].Chin J Clin Pharmacol,2017,33(4):365-368.
[2]
邱仁宗,翟晓梅.在国际背景下我国伦理审查的能力建设:理念和实践[J].中国医学伦理学,2008,21(2):3-5.Qiu RZ,Zhai XM.The construction of ethics review capacity in China under the current international conditions:conception and practice[J].Chinese Medical Ethics,2008,21(2):3-5.
[3]
白楠,王冬,曹江,等.医学伦理委员会的SIDCER和AAHRPP认证探讨[J].中国临床药理学杂志,2013,29(10):786-788.Bai N,Wang D,Cao J,et al.Knowledge of the SIDCER and AAHRPP recognition of the medical ethics committee[J].Chin J Clin Pharmacol,2013,29(10):786-788.
[4]
樊建军,杨励.北京大学临床研究现状分析及其对策建议[J].中华医学科研管理杂志,2010,23(6):365-366.Fan JJ,Yang L.Analysis of the status quo of clinical research of Peking University and countermeasures[J].Chinese Journal of Medical Science Research Management,2010,23(6):365-366.
[5]
闫永波,李野.我国药物临床试验法规与相关国际法规的对比研究[J].中国新药杂志,2011,20(17):1 612-1 614.Yan YB,Li Y.Comparison of Chinese clinical trial regulation system with relevant international law[J].Chinese Journal of New Drugs,2011,20(17):1 612-1 614.
[6]
王冬,江学维,王瑾.我国伦理委员会现状分析[J].中国临床药理学杂志,2014,30(4):381-382.Wang D,Jiang XW,Wang J.Status analysis of institutional review board in China[J].Chin J Clin Pharmacol,2014,30(4):381-382.
[7]
张金钟.生物医药研究伦理审查的体制机制建设[J].医学与哲学,2013,34(5):17-21.Zhang JZ.The system and mechanism construction of ethical review in biomedical research[J].Medicine and Philosophy,2013,34(5):17-21.
